March 31st is the deadline for the completing your step 1 risk evaluation on potential nitrosamine impurities in medical products. These highly toxic compounds, some of which are considered to be even more carcinogenic than currently established thresholds, are subject to strict regulation in both the EU and US.
Let SAXOCON help you to fill in any gaps in your supply chain information and assess their impact on your drug substances and products.
Check out how we can help here.